The Intellectual Property & Science business of Thomson Reuters is pleased to announce the winners for the Allicense 2016 Breakthrough Awards, honoring the leading deals of 2015 in Biopharmaceutical Licensing and in Mergers and Acquisitions (M&A).
Bristol-Myers Squibb’s acquisition of Cardioxyl Pharmaceuticals took top honors in the Mergers and Acquisitions (M&A) category, and the partnership between Gilead Sciences and Galapagos won the award for top Biopharmaceutical Licensing Deal.
This year’s nominees included five contenders in each of the two categories, and were determined using Thomson Reuters Recap, a deal maker’s solution that offers rapid insight and reports for biopharmaceutical key business development and licensing decisions. Exclusive BioWorld links are provided below for additional information on each deal.
Acquisition of 56.3% majority stake in Foundation Medicine for $1.03B in equity
Acquisition of Quanticel for $100M in upfront and $385M in research, development, and regulatory milestones
Cancer and autoimmune
DEAL OF THE YEAR NOMINEES: MERGERS AND ACQUISITIONS
Please note the buyer and seller company names are linked - click through for background information on each of these innovative alliances exclusively provided for you from Thomson Retuers' products Recap and BioWorld.
DEAL OF THE YEAR NOMINEES: LICENSING
Please note the licensee and licensor company names are linked - click through for background information on each of these innovative alliances exclusively provided for you from Thomson Retuers' products Recap and BioWorld.
LicenseeLicensor Total Deal Size Upfront + EquitySubject StageTherapeutic Area